FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer

May 4, 2018 – The U.S. Food and Drug Administration approved dabrafenib and trametinib, administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive). “This is the first FDA-approved treatment for patients with this aggressive form of thyroid cancer, and the third cancer with this specific gene … (leggi tutto)